Abbott reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.

The US Food and Drug Administration (FDA) has expanded the indication for the MitraClip (Abbott) device to include patients with normal mitral valves who develop symptoms of heart failure and moderate ...

Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at ...

Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, ...

ABBOTT PARK, Ill., Aug. 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company's Navitor™ transcatheter aortic valve ...